JP2006516981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006516981A5 JP2006516981A5 JP2006501762A JP2006501762A JP2006516981A5 JP 2006516981 A5 JP2006516981 A5 JP 2006516981A5 JP 2006501762 A JP2006501762 A JP 2006501762A JP 2006501762 A JP2006501762 A JP 2006501762A JP 2006516981 A5 JP2006516981 A5 JP 2006516981A5
- Authority
- JP
- Japan
- Prior art keywords
- agents
- crf
- cells
- maze
- thiadiazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 description 5
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- DSUGVVQJCVIUIV-UHFFFAOYSA-N 4,6-dimethyl-2,1,3-benzothiadiazole Chemical compound C1=C(C)C=C(C)C2=NSN=C21 DSUGVVQJCVIUIV-UHFFFAOYSA-N 0.000 description 1
- FDIMQEBEDLZCIQ-UHFFFAOYSA-N 5,7-dimethyl-4-nitro-2,1,3-benzothiadiazole Chemical compound [O-][N+](=O)C1=C(C)C=C(C)C2=NSN=C21 FDIMQEBEDLZCIQ-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000001593 cAMP accumulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0302876.8A GB0302876D0 (en) | 2003-02-07 | 2003-02-07 | Organic compounds |
| PCT/EP2004/001126 WO2004069257A1 (en) | 2003-02-07 | 2004-02-06 | Benzo (1,2,5) thiadiazole als crf-antagonisten |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006516981A JP2006516981A (ja) | 2006-07-13 |
| JP2006516981A5 true JP2006516981A5 (enExample) | 2007-03-15 |
Family
ID=9952652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006501762A Pending JP2006516981A (ja) | 2003-02-07 | 2004-02-06 | Ｃｒｆ−アンタゴニストとしてのベンゾ（１，２，５）チアジアゾール |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20070142407A1 (enExample) |
| EP (1) | EP1594506A1 (enExample) |
| JP (1) | JP2006516981A (enExample) |
| CN (1) | CN1738625A (enExample) |
| AR (1) | AR043037A1 (enExample) |
| BR (1) | BRPI0407328A (enExample) |
| CA (1) | CA2512514A1 (enExample) |
| GB (1) | GB0302876D0 (enExample) |
| PE (1) | PE20050387A1 (enExample) |
| TW (1) | TW200502235A (enExample) |
| WO (1) | WO2004069257A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0302876D0 (en) * | 2003-02-07 | 2003-03-12 | Novartis Ag | Organic compounds |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| EP2531510B1 (en) | 2010-02-01 | 2014-07-23 | Novartis AG | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
| ES2527849T3 (es) | 2010-02-02 | 2015-01-30 | Novartis Ag | Derivados de ciclohexilamida como antagonistas del receptor de CRF |
| US8546416B2 (en) | 2011-05-27 | 2013-10-01 | Novartis Ag | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists |
| CN104271579A (zh) | 2012-05-03 | 2015-01-07 | 诺华股份有限公司 | 作为生长素释放肽受体激动剂的2,7-二氮杂-螺[4,5]癸烷-7-基衍生物的l-苹果酸盐及其结晶 |
| EP2750275B1 (en) | 2012-12-31 | 2016-11-16 | Nxp B.V. | Low loss mains detection with sampling suspension for PFC SMPS |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9323290D0 (en) * | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| GB9802251D0 (en) * | 1998-02-03 | 1998-04-01 | Ciba Geigy Ag | Organic compounds |
| US6756367B2 (en) * | 1998-02-03 | 2004-06-29 | Novartis Ag | Benzo-oxadiazoles, -thiadiazoles and -1,4-diazines, pharmaceutical compositions containing them and a process for preparing them |
| GB0302876D0 (en) * | 2003-02-07 | 2003-03-12 | Novartis Ag | Organic compounds |
-
2003
- 2003-02-07 GB GBGB0302876.8A patent/GB0302876D0/en not_active Ceased
-
2004
- 2004-02-05 PE PE2004000133A patent/PE20050387A1/es not_active Application Discontinuation
- 2004-02-05 AR ARP040100364A patent/AR043037A1/es not_active Application Discontinuation
- 2004-02-06 US US10/544,693 patent/US20070142407A1/en not_active Abandoned
- 2004-02-06 JP JP2006501762A patent/JP2006516981A/ja active Pending
- 2004-02-06 EP EP04708753A patent/EP1594506A1/en not_active Withdrawn
- 2004-02-06 WO PCT/EP2004/001126 patent/WO2004069257A1/en not_active Ceased
- 2004-02-06 BR BR0407328-2A patent/BRPI0407328A/pt not_active IP Right Cessation
- 2004-02-06 CA CA002512514A patent/CA2512514A1/en not_active Abandoned
- 2004-02-06 CN CNA2004800023436A patent/CN1738625A/zh active Pending
- 2004-02-06 TW TW093102807A patent/TW200502235A/zh unknown
-
2010
- 2010-06-24 US US12/822,697 patent/US20100280053A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5395844B2 (ja) | イミダゾ［４，５−ｃ］ピリジン化合物および抗ウイルス治療の方法 | |
| CN100368411C (zh) | 作为c-Jun N-末端激酶抑制剂用于治疗神经变性疾病的7-氮杂吲哚类化合物 | |
| AU2005287407B2 (en) | Imidazo(4,5-d)pyrimidines, their uses and methods of preparation | |
| CA2932121A1 (en) | Ido inhibitors | |
| EP2595993B1 (en) | Tricyclic proteasome activity enhancing compounds | |
| KR100507250B1 (ko) | 벤조티아디아졸 및 유도체 | |
| FR2823209A1 (fr) | Nouvelles thiohydantoines et leur utilisation en therapeutique | |
| NZ588431A (en) | Using Benzimidazole or Indole compounds with a 1,2-diazole group to Inhibit Alpha-Synuclein Toxicity | |
| KR20050107611A (ko) | 구아니딘 유도체 및 신경펩티드 ｆｆ 수용체 길항제로서이들의 용도 | |
| JP2006516981A5 (enExample) | ||
| EP1418912B1 (en) | Isoxazolopyridinones | |
| EP3472133B1 (en) | Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins | |
| JP2004512364A (ja) | 中枢神経系疾患の治療のためのスルホンアミド | |
| CN118176202B (zh) | 一种含氰基取代的多肽类化合物的晶型及其制备方法 | |
| JP2006516981A (ja) | Ｃｒｆ−アンタゴニストとしてのベンゾ（１，２，５）チアジアゾール | |
| HK1211918A1 (en) | Coumarin derivative | |
| US8183388B2 (en) | Androgen receptor modulator and uses thereof | |
| JPH01250364A (ja) | ヒドロキシピリミジン類のアシル誘導体および組成物 | |
| JP2013536808A (ja) | Ｋｃｎｑ２／３調節因子としての置換１−オキソ−ジヒドロイソキノリン−３−カルボキサミド | |
| WO2022056448A1 (en) | Tetrahydroisoquinoline derivatives for the treatment of red blood disorders and inflammatory diseases | |
| CA2350560C (en) | Novel type condensed pyridazinone compounds | |
| AU2012268119A1 (en) | [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid | |
| RU2780247C1 (ru) | ПРИМЕНЕНИЕ ТРИЦИКЛИЧЕСКОГО СЕРУСОДЕРЖАЩЕГО ПРОИЗВОДНОГО 1,2-ДИГИДРОХИНОЛИНА ДЛЯ ИНГИБИРОВАНИЯ РЕПЛИКАЦИИ БЕТА-КОРОНАВИРУСОВ, ВКЛЮЧАЯ SARS-CoV-2 | |
| JP2003252875A (ja) | 新規プリン誘導体 | |
| US20230381174A1 (en) | Thionoester-derivative of rabeximod for the treatment of inflammatory and autoimmune disorders |